Results of CHOP with or without rituximab in elderly diffuse large B cell lymphoma (DLCL-B).
| Study . | Therapy . | 2-Year TTF . | 2-Year OS . |
|---|---|---|---|
| Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; TTF, time to treatment failure; OS, overall survival; SWOG, Southwest Oncology Group; GELA, Groupe d’Etude des Lymphomes de l’Adulte; ECOG, Eastern Cooperative Oncology Group | |||
| SWOG-85161 | CHOP | 49% | 60% |
| GELA6 | CHOP | 40% | 60% |
| CHOP-Rituximab | 58% | 72% | |
| ECOG-44947 | CHOP | 55% | 65% |
| CHOP-Rituximab | 65% | 71% | |
| Study . | Therapy . | 2-Year TTF . | 2-Year OS . |
|---|---|---|---|
| Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; TTF, time to treatment failure; OS, overall survival; SWOG, Southwest Oncology Group; GELA, Groupe d’Etude des Lymphomes de l’Adulte; ECOG, Eastern Cooperative Oncology Group | |||
| SWOG-85161 | CHOP | 49% | 60% |
| GELA6 | CHOP | 40% | 60% |
| CHOP-Rituximab | 58% | 72% | |
| ECOG-44947 | CHOP | 55% | 65% |
| CHOP-Rituximab | 65% | 71% | |